Prognostic Effects of Cholesterol Levels in Patients with Breast Cancer
Keywords:
HDL cholesterol, LDL cholesterol, breast cancer, prognosis, survivalAbstract
High cholesterol level has been found to be a risk factor for breast cancer. However, few studies have reported on their prognostic impact. This study aimed to determine the effect of cholesterol level on breast-cancer prognosis. Cholesterol levels were detected in 142 cases of breast cancer diagnosed at the National Cancer Institute in 2011-2018. We found that low levels of HDL cholesterol (≤65 mg/dL) were mainly present in breast-cancer patients with lymph-node metastasis (P=0.037) and negative progesterone receptor (P=0.045). However, this study revealed no association between HDL cholesterol level and age, stage, estrogen receptor, P53, Ki67, HER-2 and the overall survival of the patients. Our findings suggested that a low level of HDL cholesterol may correlate with a poor prognosis in breast cancer.(Thai Cancer J 2020;40:86-97)
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. Available from: http://doi.wiley.com/10.3322/caac.21492. Accessed Jul 10, 2020.
Imsamran W, Chaiwerawattana A, Wiangnon S,Pongnikorn D, Suwanrungrung K, Sangrajrang S, et al. Cancer in Thailand: Vol.VIII,2010- 2012. Available from: http://www.nci.go.th/th/
File_download/Nci%20Cancer%20Registry/Cancer%20in%20Thailand8.pdf. Accessed July 10, 2020.
Chaiwerawattana A, Loawahutanon P SP. Hospital-based cancer registry annual report 2012.Availablefrom:http://www.nci.go.th/th/File_ download/Nci%20Cancer%20Registry/Hospital-Based%20NCI%202012%20 Total.pdf.Accessed July 10, 2020.
Dumitrescu RG, Cotarla I. Understanding breast cancer risk where do we stand in 2005?. J Cell Mol Med 2005;9:208-21.
Fiorenza AM, Branchi A, Sommariva D. Serum lipo- protein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000; 30:141-5.
Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:1-7.
Kökoglu E, Karaarslan I, Karaarslan HM, Baloglu H. Alterations of serum lipids and lipoproteins in breast cancer. Cancer Lett 1994;82:175-8.
Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol 2012;12:677-82.
Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endo metrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008;630:148-65.
Kitahara CM, De González AB, Freedman ND, Huxley R, Mok Y, Jee SH, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011;29:1592-8.
Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer.Br J Cancer 2002;86:1436-9.
Emaus A, Veierød MB, Tretli S, Finstad SE Selmer R, Furberg A-S,et al. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 2010;121:651-60.
Eliassen AH, Colditz GA, Rosner B, Willett WC,Hankinson SE. Serum lipids, lipid-lowering drugs,and the risk of breast cancer. Arch Intern Med. Available from: https: //doi.org/10.1001/archinte.
19.2264. Accessed July 10, 2020.
Vatten LJ, Foss OP. Total serum cholesterol and triglycerides and risk of breast cancer: a prospective study of 24, 329 Norwegian women.Cancer Res 1990;50: 2341-6.
Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, et al. Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). PLoS
One 2013;8:e54242
Li X, Liu ZL, Wu YT, Wu H, Dai W, Arshad B, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis 2018;17:1-6.
His M, Dartois L, Fagherazzi G, Boutten A, DupréT, Mesrine S, et al. Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes Control 2017;28:77–88.
Lofterød T, Mortensen ES, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T, et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer 2018;18:1-11.
Samadi S, Ghayour-Mobarhan M, Mohammadpour A, Farjami Z, Tabadkani M, Hossein nia M, et al. High-density lipoprotein functionality and breast cancer: A potential therapeutic target. J Cell Biochem 2019;120:5756-65.
Cruz PMR, Mo H, McConathy WJ, Sabnis N, Lacko AG. The role of cholesterol metabolism and cholesterol transport in carcinogenesis A review of scientific findings, relevant to future cancer
therapeutics. Front Pharmacol 2013;4:1-7.
Furberg A-S, Veierød MB, Wilsgaard T, Bernstein L , Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96:1152–60.
Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohortstudy. Ann Epidemiol 2008;18:671-7.
Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH, et al. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status,body mass index, and hormonal receptor in Korea. Cancer Epidermiol Biomarkers Prev 2009;18:508-15.
Rodrigues dos Santos C, Fonseca I, Dias S, de Almeida JCM. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer 2014;14:1-10.
Harris L, Fritsche H, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:
-312.
Hanash SM, Pitteri SJ, Faca VM, Mining the plasma proteome for cancer biomarkers. Nature 2008;452:571-9.
Murai T. Cholesterol lowering: role in cancer prevention and treatment. Biol Chem 2015;396:1-11.
Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013;32:961-7
Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, et al. Dietary fat increases solid tumor growth and metastasis of 4 T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 2011;13:R78.
Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg AS, et al. Metabolic profile,physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 2010 ,121:651-60.
Iso H, Ikeda A, Inoue M, Sato S, Tsugane S: Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009;125:2679-86.
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71.
Ha M, Sung J, Song YM. Serum total Cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer causes control 2009;20:1055-60.
Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in cancer of women. Indian J Clin Biochem 2005;20:61-6.
de Azambuja E, Cardoso F, de Castro G Jr,Colozza M, Mano MS, Durbecq V, et al. Ki-67 asprognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
Br J Cancer 2007;96:1504-13.
Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, et al. The effect of preoperative serum triglycerides and high-density lipoprotein- cholesterol levels on the prognosis of breast cancer. Breast 2017;32:1-6.
Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Bio chem 2001;34:71-6.
Esteve E, Ricart W, Fernandez-real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005; 24:16-31.
Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005;90:113-5.
Downloads
Published
Issue
Section
License
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
